Drugs News and Research

RSS

Xenogenics acquires Ideal BioStent assets

MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.

19 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Pharmacy graduate awarded national recognition for pioneering research in genetics

A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.

19 Oct 2010

Research calls for better environmental risk assessments of pharmaceuticals

The strategies used to assess the environmental risks posed by pharmaceuticals are not enough to protect natural microbial communities, reveals a researcher from the University of Gothenburg (Sweden) who is calling for better environmental risk assessments.

19 Oct 2010

TearLab announces publication of CPT code for Osmolarity test

TearLab Corporation announced today that, further to its press release of October 8, 2010, a unique new Current Procedural Terminology code that will apply to the TearLab Osmolarity test has now been published by the American Medical Association. The new code will become effective January 1, 2011.

19 Oct 2010

First Edition: October 19, 2010

Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.

19 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

UnitedHealth Group consolidated third quarter revenues increase 9% to $23.7 billion

UnitedHealth Group today reported third quarter results, including strong revenue growth in both its Health Benefits and Health Services business groups. Third quarter 2010 net earnings were $1.14 per share. Key performance metrics and costs were in line with or better than Company expectations.

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain

Substantial and sustained reduction in pain scores were reported in the middle and high dose cohorts of Diamyd Medical's Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain. No treatment related Serious Adverse Events have been observed in the study to date.

19 Oct 2010

60 Plus applauds FDA decision to remove unapproved colchicine products

James L. Martin, chairman of the 60 Plus Association, a seniors advocacy group, applauded the Food and Drug Administration's (FDA) decision to remove unapproved colchicine products from the market, and called on drug manufacturers, distributors and pharmacies to help the FDA protect patients from unapproved drugs.

19 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry.

19 Oct 2010

Long-term use of statins reduces colorectal cancer risk

A systematic review of the medical literature supports the hypothesis that statins, cholesterol-lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers.

19 Oct 2010

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA "hotspots" that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

19 Oct 2010

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer's disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer's disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

19 Oct 2010

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Dopamine behind mens susceptibility to alcoholism

Alcohol is one of the most commonly abused substances, and men are up to twice as likely to develop alcoholism as women. Until now, the underlying biology contributing to this difference in vulnerability has remained unclear.

19 Oct 2010

Drugs News and Research

Xenogenics acquires Ideal BioStent assets

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Pharmacy graduate awarded national recognition for pioneering research in genetics

Research calls for better environmental risk assessments of pharmaceuticals

TearLab announces publication of CPT code for Osmolarity test

First Edition: October 19, 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

UnitedHealth Group consolidated third quarter revenues increase 9% to $23.7 billion

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Few legitimate opioid users are getting information to keep medications safe

Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain

60 Plus applauds FDA decision to remove unapproved colchicine products

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

Long-term use of statins reduces colorectal cancer risk

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Researchers identify new mechanism that could help develop effective chemotherapy drug

Dopamine behind mens susceptibility to alcoholism

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News